Overall, our study demonstrates that the concurrent re-expression of DIRAS3 and p53 induces multiple anti-tumor effects and suggests a more effective approach for the treatment of HNSCC than the currently used treatment strategies. The gene discussed is TP53; the disease is neoplasm.